{
    "nctId": "NCT01077453",
    "briefTitle": "Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer",
    "officialTitle": "Phase I Dose-Finding Trial of Letrozole in Postmenopausal Women at High Risk for Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Healthy, no Evidence of Disease, Lobular Breast Carcinoma in Situ",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 112,
    "primaryOutcomeMeasure": "Percentage of serum estradiol suppression in postmenopausal women at high risk for breast cancer",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy postmenopausal women at \"high risk\" for breast cancer will be eligible for the study; definition of menopause will be:\n\n  * Amenorrhea for at least 12 months, or\n  * History of hysterectomy and bilateral salpingo-oophorectomy, or\n  * At least 55 years of age with prior hysterectomy with or without oophorectomy, or\n  * Age 35 to 54 with a prior hysterectomy without oophorectomy OR with a status of ovaries unknown with documented follicle-stimulating hormone level demonstrating elevation in postmenopausal range\n  * \"High risk\" for breast cancer will be defined as:\n\n    * Prior histologically confirmed lobular carcinoma in situ (LCIS) treated by local excision only, or\n    * At least 1.66% probability of invasive breast cancer within 5 years using the Breast Cancer Risk Assessment Tool\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; Karnofsky 80% or above\n* Leukocytes \\>= 3,000/uL\n* Absolute neutrophil count \\>= 1,500/uL\n* Platelets \\>= 100,000/uL\n* Total bilirubin =\\< 2.0 mg/dL\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\< 2.0 X institutional ULN\n* Creatinine =\\< 1 X institutional ULN\n* Recent mammogram negative for breast cancer, Breast Imaging-Reporting and Data System (BIRADS) score \\< 3 (within the last 12 months)\n* Ability to understand and the willingness to sign a written informed consent document; only potential participants with the ability to understand and the willingness to sign a written document will be presented with an informed consenting document\n\nExclusion Criteria:\n\n* Women diagnosed with osteoporosis (previously or on screening dual-energy X-ray absorptiometry \\[DEXA\\] for this study) and not on a stable dose of long or short-acting bisphosphonates therapy for at least 3 months will be excluded from the study; women diagnosed with osteoporosis and on raloxifene (Evista) therapy will be excluded from the study; use of calcium and/or vitamin D for osteoporosis prevention or treatment is allowed; women with osteopenia will be allowed to participate in this study\n* Have had invasive cancer within the past five years except non-melanoma skin cancer\n* Evidence of suspicious of malignant disease on bilateral mammogram within the past year unless ruled out by further evaluation\n* History of prior invasive breast cancer or intraductal carcinoma in situ, or history of prior radiation therapy to the chest or breast\n* Participants may not be receiving any other investigational agents; participants may not be concurrently enrolled in another breast cancer prevention intervention trial\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to letrozole\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Within 3 months since prior estrogen or progesterone replacement therapy, oral contraceptives, androgens, luteinizing hormone-releasing hormone analogs, prolactin inhibitors, or antiandrogens\n* Within 3 months since prior tamoxifen, raloxifene, or other selective estrogen-receptor modulators\n* Within 3 months since regular use (more than 2 times a week) of prior estrogenic supplements or herbal remedies\n* History of bleeding or clotting disorder; current or recent (within 3 months) use of Coumadin, Plavix or other systemic anticoagulant other than aspirin is not permitted if subject chooses to participate in the optional RPFNA procedure; if a subject chooses not to participate in the RPFNA procedure, prior or current treatment with systemic anticoagulants is permitted",
    "sex": "FEMALE",
    "minimumAge": "35 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}